Does Rallies show Form 4 insider transactions for ZYME?

Yes. Rallies tracks ZYME insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ZYME research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ZYME. It does not provide personalized investment advice.

ZYME (Zymeworks Inc.) Stock Analysis - Insider Trades

Zymeworks Inc. (ZYME) is a publicly traded Healthcare sector company. As of May 20, 2026, ZYME trades at $24.98 with a market cap of $1.80B and a P/E ratio of -6.10. ZYME moved +1.86% today. Year to date, ZYME is -2.51%; over the trailing twelve months it is +99.84%. Its 52-week range spans $9.03 to $29.75. Analyst consensus is strong buy with an average price target of $39.89. Rallies surfaces ZYME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ZYME stock inside the company?

Recent ZYME insider activity includes Hollywood Mark sold 6.12K, Smith Jeffrey T L sold 9.31K, Moore Paul Andrew sold 9.56K, Galbraith Kenneth sold 30.42K, and Smith Jeffrey T L sold 10.54K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ZYME Key Metrics

Key financial metrics for ZYME
Metric	Value
Price	$24.98
Market Cap	$1.80B
P/E Ratio	-6.10
EPS	$-4.08
Dividend Yield	0.00%
52-Week High	$29.75
52-Week Low	$9.03
Volume	429.52K
Avg Volume	0
Revenue (TTM)	$31.62M
Net Income	$-236.97M
Gross Margin	0.00%

Recent ZYME Insider Trades

Hollywood Mark sold 6.12K (~$138.76K) on Jan 12, 2026.
Smith Jeffrey T L sold 9.31K (~$211.09K) on Jan 12, 2026.
Moore Paul Andrew sold 9.56K (~$216.76K) on Jan 12, 2026.
Galbraith Kenneth sold 30.42K (~$689.82K) on Jan 12, 2026.
Smith Jeffrey T L sold 10.54K (~$264.47K) on Jan 5, 2026.

Latest ZYME News

Zymeworks ZW191 Achieves 61% ORR and 7.6-Month PFS in Phase 1 — Apr 21, 2026
Zymeworks Showcases Six ADC Programs Including Pan-RAS Inhibitors with 1 mg/kg Efficacy — Apr 17, 2026
Zymeworks Appoints Schayowitz EVP R&D and Platshon EVP Business Officer — Apr 9, 2026
Zymeworks Appoints Former Royalty Pharma SVP Kristin Stafford as CFO — Apr 1, 2026
Zymeworks Scores FDA Fast Track for FRα-Targeting ZW191 in Ovarian Cancer — Mar 30, 2026

ZYME Analyst Consensus

11 analysts cover ZYME: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.89.

Common questions about ZYME

Who is trading ZYME stock inside the company?: Recent ZYME insider activity includes Hollywood Mark sold 6.12K, Smith Jeffrey T L sold 9.31K, Moore Paul Andrew sold 9.56K, Galbraith Kenneth sold 30.42K, and Smith Jeffrey T L sold 10.54K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ZYME?: Yes. Rallies tracks ZYME insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ZYME research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ZYME. It does not provide personalized investment advice.